Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-16-153345
Filing Date
2016-10-31
Accepted
2016-10-31 16:50:29
Documents
1
Period of Report
2016-10-31

Document Format Files

Seq Description Document Type Size
1 4 a4.html 4  
1 4 a4.xml 4 22122
  Complete submission text file 0001104659-16-153345.txt   24323
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-37926 | Film No.: 161962213
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-37926 | Film No.: 161962214

Mailing Address ONE KENDALL SQUARE SUITE B14301 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE SUITE B14301 CAMBRIDGE MA 02139 (617) 401-4060
Ra Pharmaceuticals, Inc. (Issuer) CIK: 0001481512 (see all company filings)

EIN.: 262908274 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations